

# John R Bradley

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6116061/publications.pdf>

Version: 2024-02-01

42  
papers

6,682  
citations

218677

26  
h-index

276875

41  
g-index

49  
all docs

49  
docs citations

49  
times ranked

15130  
citing authors

#	ARTICLE	IF	CITATIONS
1	Co-Expression and Functional Interactions of Death Receptor 3 and E-Selectin in Clear Cell Renal Cell Carcinoma. <i>American Journal of Pathology</i> , 2022, 192, 722-736.	3.8	2
2	B cell receptor repertoire kinetics after SARS-CoV-2 infection and vaccination. <i>Cell Reports</i> , 2022, 38, 110393.	6.4	29
3	Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity. <i>Nature</i> , 2022, 603, 706-714.	27.8	756
4	Coagulation factor V is a T-cell inhibitor expressed by leukocytes in COVID-19. <i>IScience</i> , 2022, 25, 103971.	4.1	7
5	The impact of hypoxia on B cells in COVID-19. <i>EBioMedicine</i> , 2022, 77, 103878.	6.1	15
6	Evidence of previous SARS-CoV-2 infection in seronegative patients with long COVID. <i>EBioMedicine</i> , 2022, 81, 104129.	6.1	21
7	SARS-CoV-2 evolution during treatment of chronic infection. <i>Nature</i> , 2021, 592, 277-282.	27.8	802
8	Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies. <i>Nature</i> , 2021, 593, 136-141.	27.8	648
9	Challenges and opportunities for conducting a vaccine trial during the COVID-19 pandemic in the United Kingdom. <i>Clinical Trials</i> , 2021, 18, 615-621.	1.6	3
10	Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2. <i>Nature</i> , 2021, 596, 417-422.	27.8	549
11	Longitudinal analysis reveals that delayed bystander CD8+ T cell activation and early immune pathology distinguish severe COVID-19 from mild disease. <i>Immunity</i> , 2021, 54, 1257-1275.e8.	14.3	230
12	Point of Care Nucleic Acid Testing for SARS-CoV-2 in Hospitalized Patients: A Clinical Validation Trial and Implementation Study. <i>Cell Reports Medicine</i> , 2020, 1, 100062.	6.5	47
13	Combined Point-of-Care Nucleic Acid and Antibody Testing for SARS-CoV-2 following Emergence of D614G Spike Variant. <i>Cell Reports Medicine</i> , 2020, 1, 100099.	6.5	61
14	Signaling through tumor necrosis receptor 2 induces stem cell marker in CD133+ regenerating tubular epithelial cells in acute cell-mediated rejection of human renal allografts. <i>American Journal of Transplantation</i> , 2020, 20, 2380-2391.	4.7	2
15	Effect of kidney donation on bone mineral metabolism. <i>PLoS ONE</i> , 2020, 15, e0235082.	2.5	3
16	Tumor necrosis factor receptor 2 signaling pathways promote survival of cancer stem-like CD133 <sup>+</sup> cells in clear cell renal carcinoma. <i>FASEB BioAdvances</i> , 2020, 2, 126-144.	2.4	7
17	The Efficacy of Sunitinib Treatment of Renal Cancer Cells Is Associated with the Protein PHAX In Vitro. <i>Biology</i> , 2020, 9, 74.	2.8	2
18	Screening of healthcare workers for SARS-CoV-2 highlights the role of asymptomatic carriage in COVID-19 transmission. <i>ELife</i> , 2020, 9, .	6.0	423

#	ARTICLE	IF	CITATIONS
19	Effective control of SARS-CoV-2 transmission between healthcare workers during a period of diminished community prevalence of COVID-19. <i>ELife</i> , 2020, 9, .	6.0	40
20	The Genetic Links to Anxiety and Depression (GLAD) Study: Online recruitment into the largest recontactable study of depression and anxiety. <i>Behaviour Research and Therapy</i> , 2019, 123, 103503.	3.1	47
21	Germline selection shapes human mitochondrial DNA diversity. <i>Science</i> , 2019, 364, .	12.6	178
22	TNFR2 ligation in human T regulatory cells enhances IL2-induced cell proliferation through the non-canonical NF- $\kappa$ B pathway. <i>Scientific Reports</i> , 2018, 8, 12079.	3.3	36
23	A 3D tri-culture system reveals that activin receptor-like kinase 5 and connective tissue growth factor drive human glomerulosclerosis. <i>Journal of Pathology</i> , 2017, 243, 390-400.	4.5	8
24	Human Organ Culture: Updating the Approach to Bridge the Gap from In Vitro to In Vivo in Inflammation, Cancer, and Stem Cell Biology. <i>Frontiers in Medicine</i> , 2017, 4, 148.	2.6	37
25	Book ReviewsOxford Textbook of Medical Education Edited by KieranWalsh Oxford University Press 2016 Price $\pounds$ 95.00. Pp 776 ISBN 9780198785712Understanding Kidney Diseases HughRayner, MarkThomas, DavidMilford Springer 2016 Price $\pounds$ 89.50. Pp 300 ISBN 9783319234571Textbook of Pleural Diseases (3rd) Tj ETQp.1 0.784314 rgBT <i>British Journal of Hospital Medicine (London, England, 2005)</i> , 2016, 77, 422-423.	1.1	14
26	The Allelic Landscape of Human Blood Cell Trait Variation and Links to Common Complex Disease. <i>Cell</i> , 2016, 167, 1415-1429.e19.	28.9	1,052
27	Phenotypic screening reveals TNFR2 as a promising target for cancer immunotherapy. <i>Oncotarget</i> , 2016, 7, 68278-68291.	1.8	48
28	Tumor necrosis factor receptor 2-signaling in CD133-expressing cells in renal clear cell carcinoma. <i>Oncotarget</i> , 2016, 7, 24111-24124.	1.8	16
29	DR3 Signaling Protects against Cisplatin Nephrotoxicity Mediated by Tumor Necrosis Factor. <i>American Journal of Pathology</i> , 2012, 180, 1454-1464.	3.8	15
30	Tumor Necrosis Factor Receptor Expression and Signaling in Renal Cell Carcinoma. <i>American Journal of Pathology</i> , 2010, 177, 943-954.	3.8	58
31	TL1A Both Promotes and Protects from Renal Inflammation and Injury. <i>Journal of the American Society of Nephrology: JASN</i> , 2008, 19, 953-960.	6.1	68
32	TNFR1- and TNFR2-mediated signaling pathways in human kidney are cell type-specific and differentially contribute to renal injury. <i>FASEB Journal</i> , 2005, 19, 1637-1645.	0.5	134
33	Caveolae Participate in Tumor Necrosis Factor Receptor 1 Signaling and Internalization in a Human Endothelial Cell Line. <i>American Journal of Pathology</i> , 2005, 166, 1273-1282.	3.8	98
34	Expression of Silencer of Death Domains and Death-Receptor-3 in Normal Human Kidney and in Rejecting Renal Transplants. <i>American Journal of Pathology</i> , 2003, 163, 401-411.	3.8	28
35	Expression of Tumor Necrosis Factor Receptors in Normal Kidney and Rejecting Renal Transplants. <i>Laboratory Investigation</i> , 2001, 81, 1503-1515.	3.7	116
36	Tumor necrosis factor receptor-associated factors (TRAFs). <i>Oncogene</i> , 2001, 20, 6482-6491.	5.9	593

#	ARTICLE	IF	CITATIONS
37	Growth of porcine kidneys in their native and xenograft environment. <i>Xenotransplantation</i> , 2000, 7, 96-100.	2.8	34
38	Osteoclastic Tartrate-resistant Acid Phosphatase (Acp 5): Its Localization to Dendritic Cells and Diverse Murine Tissues. <i>Journal of Histochemistry and Cytochemistry</i> , 2000, 48, 219-227.	2.5	126
39	Cellular and Subcellular Distribution of Polycystin-2, the Protein Product of the PKD2 Gene. <i>Journal of the American Society of Nephrology: JASN</i> , 2000, 11, 814-827.	6.1	145
40	8 Tumour necrosis factor induced autophagy and mitochondrial morphological abnormalities are mediated by TNFR-I and/or TNFR-II and do not invariably lead to cell death. <i>Biochemical Society Transactions</i> , 1998, 26, S314-S314.	3.4	14
41	11 Tumour necrosis factor is trafficked to a mitochondrial tumour necrosis factor binding protein. <i>Biochemical Society Transactions</i> , 1998, 26, S316-S316.	3.4	2
42	Impaired Nutritive Skeletal Muscle Blood Flow in Patients with Chronic Renal Failure. <i>Clinical Science</i> , 1990, 79, 239-245.	4.3	43